Whitelab Genomics Analysis: $10M Raised
What is Whitelab Genomics?
Whitelab Genomics utilizes AI and biological data to enhance drug development in genomic medicine, focusing on the safety and efficacy of therapeutic candidates.
Employees
25
Founded
2019
Revenue
$7.4M
Business Model
Collaborative partnerships and funding for AI-driven genomic therapy development.
Product Features & Capabilities
- Gene & RNA-based therapies, Target Receptors Identification, Viral Vector Design, Non-Viral Vector Design, Payload Design, Bioproduction Optimization, Cell Therapy Pipeline.
How much Whitelab Genomics raised
1 - $10 million
September 12, 2022Lead Investor: Omnes Capital, Debiopharm
Who are the founders of Whitelab Genomics
DD
David Delbourgo
Founder
JC
Julien Cottineau
Founder
Investors
- WhiteLab Genomics has raised $10 million in funding.
- The funding round was led by investors including:
- Alven Capital
- Bpifrance
- Eurazeo
- Kima Ventures
Market Focus
Whitelab Genomics primarily focuses on the genomic medicine industry, specifically in optimizing biological data and artificial intelligence to enhance the development of pre-clinical genomic therapies.
Competitors Overview
Whitelab Genomics operates in the genomic medicine sector, focusing on the optimization of biological data and AI for pre-clinical genomic therapies. Its main competitors include:
- Owkin: Specializes in AI-driven drug discovery and development, particularly in oncology. Owkin's advantage lies
See something that needs updating? Suggest edits to this profile.